Precigen Actobio

Foundation date

03/07/2006

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Precigen ActoBio™ is a clinical stage biotechnology company pioneering a new class of therapeutic agents created on the ActoBiotics™ platform. These are targeted, microbe-based, specifically designed agents that express and locally deliver potential disease-modifying therapeutics at disease sites including the intestine, the mouth and the nasopharynx, to treat a range of disorders.

We have a strong R&D pipeline and an extensive portfolio of candidates advancing toward clinical development across a number of potential indications.

Precigen ActoBio™ is a wholly-owned subsidiary of Precigen.

Upcoming events

Latest news

  • Mithra appoints experienced life sciences executive Christian Homsy* as Chairman

    12 hours ago

  • Oxurion reaches enrollment target in KALAHARI Phase 2, Part B trial of novel PKal inhibitor THR-149 in diabetic macular edema

    Friday May 26th 2023

  • How garbage disposal clogs in cells can lead to Alzheimer’s

    Friday May 26th 2023